Pomegranate seed oil in women with menopausal symptoms: A prospective randomized, placebo-controlled, double-blinded trial

Menopause

Volumn 19, Issue 4, 2012, Pages 426-432

  Auerbach, Leo ^a   Rakus, Julia ^a   Bauer, Clemens ^a   Gerner, Christopher ^b   Ullmann, Ronald ^c   Wimmer, Helge ^d   Huber, Johannes ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c University of Applied Sciences ^*  (Germany)

^d UNIVERSITY OF APPLIED SCIENCES   (Austria)

Author keywords

Hot flashes; Menopausal symptoms; Menopause Rating Scale II; Phytoestrogens; Pomegranate seed oil; Sleeping disorders

Indexed keywords

PHYTOESTROGEN; PLACEBO; POMEGRANATE SEED OIL; UNCLASSIFIED DRUG; VEGETABLE OIL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PLANT SEED; POMEGRANATE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP DISORDER; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PLANT OILS; PROSPECTIVE STUDIES; PUNICACEAE; QUALITY OF LIFE; SEEDS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 84859428387     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182345b2f     Document Type: Article

References (64)

1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
2. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003;10:19-28. (Pubitemid 36706318)
3. Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196:97-106. (Pubitemid 46240000)
4. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Ehrlich K. Night sweats, sleep disturbance, and depression associated with diminished libido in late menopausal transition and early postmenopause: baseline data from the Herbal Alternatives for Menopause Trial (HALT). Am J Obstet Gynecol 2007;196:593e1-593e7.
5. Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. JAMA 1959;171:1627-1637.
6. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal complaints. Climacteric 2000;3:59-64. (Pubitemid 30354485)
7. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316. (Pubitemid 29149109)
8. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332-337. (Pubitemid 28361490)
9. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142: 1003-1013.
10. Bachmann GA. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005;50: 155-165. (Pubitemid 40393256)
11. Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000;6:225-236. (Pubitemid 30348891)
12. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
13. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288:872-881.
14. Shen W, Stearns V. Treatment strategies for hot flushes. Expert Opin Pharmacother 2009;10:1133-1144.
15. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.
16. Shapiro S, Farmer RD, Seaman H, Stevenson JC, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011;37:103-109.
17. Howell A, Evans GD. Hormone replacement therapy and breast cancer [review]. Recent Results Cancer Res 2011;188:115-124.
18. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360: 942-944. (Pubitemid 35283842)
19. Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369: 1703-1710. (Pubitemid 46755369)
20. Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: a review. Mol Cell Endocrinol 2009;304:30-42.
21. Albertazzi P, Purdie DW. The nature and utility of the phytoestrogens: A review of the evidence. Maturitas 2008;61:214-226.
22. Tempfer CB, Bentz EK, Leodolter S, et al. Phytoestrogens in clinical practice: a review of the literature. Fertil Steril 2007;87:1243-1249. (Pubitemid 46829161)
23. Alm YH, Sukjumlong S, Kindahl H, Dalin AM. Steroid hormone receptors ER> and PR characterised by immunohistochemistry in the mare adrenal gland. Acta Vet Scand 2009;51:31.
24. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptomsVa systematic review. Mol Nutr Food Res 2009;53:1084-1097.
25. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071. (Pubitemid 44794007)
26. Kaufman M, Wiesman Z. Pomegranate oil analysis with emphasis on MALDI-TOF/MS triacylglycerol fingerprinting. J Agric Food Chem 2007;55:10405-10413.
27. Caligiani A, Bonzanini F, Palla G, Cirlini M, Bruni R. Characterization of a potential nutraceutical ingredient: pomegranate (Punica granatum L.) seed oil unsaponifiable fraction. Plant Foods Hum Nutr 2010;65:277-283.
28. Tran HN, Bae SY, Song BH, et al. Pomegranate (Punica granatum) seed linolenic acid isomers: concentration-dependent modulation of estrogen receptor activity. Endocr Res 2010;35:1-16.
29. Jurenka JS. Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 2008;13:128-144.
30. Stowe CB. The effects of pomegranate juice consumption on blood pressure and cardiovascular health. Complement Ther Clin Pract 2011;17: 113-115.
31. Vroegrijk IO, van Diepen JA, van den Berg S, et al. Pomegranate seed oil, a rich source of punicic acid, prevents diet-induced obesity and insulin resistance in mice. Food Chem Toxicol 2011;49:1426-1430.
32. Sturgeon SR, Ronnenberg AG. Pomegranate and breast cancer: possible mechanisms of prevention. Nutr Rev 2010;68:122-128.
33. Kasimsetty SG, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 2010;58:2180-2187.
34. Adhami VM, Khan N, Mukhtar H. Cancer chemoprevention by pomegranate: laboratory and clinical evidence. Nutr Cancer 2009;61:811-815.
35. Koyama S, Cobb LJ, Mehta HH, et al. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGFIGFBP axis. Growth Horm IGF Res 2010;20:55-62.
36. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancerVa mini review. J Pharm Pharmacol 2008;60:139-144. (Pubitemid 351211828)
37. Adhami VM, Mukhtar H. Anti-oxidants from green tea and pomegranate for chemoprevention of prostate cancer. Mol Biotechnol 2007;37:52-57. (Pubitemid 350135905)
38. Seeram NP, Aronson WJ, Zhang Y, et al. Pomegranate ellagitanninderived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 2007;55:7732-7737. (Pubitemid 47522181)
39. Adhami VM, Mukhtar H. Polyphenols from green tea and pomegranate for prevention of prostate cancer. Free Radic Res 2006;40:1095-1104. (Pubitemid 44480550)
40. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005;102:14813-14818. (Pubitemid 41457138)
41. Pantuck AJ, Leppert JT, Zomorodian N, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;12: 4018-4026. (Pubitemid 44078089)
42. Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. J Ethnopharmacol 2004;92:93-101. (Pubitemid 38510269)
43. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. The Menopause Rating Scale (MRS II): methodological standardization in the German population [in German]. Zentralbl Gynakol 2000;122: 280-286.
44. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2004;2:45.
45. Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metabol 2005;90:1390-1397. (Pubitemid 40463994)
46. Erkkola R, Vervarcke S, Vansteelandt S, Rompotti P, De Keukeleire D, Heyerick A. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine 2010;17:389-396.
47. Bolanos R, Del Castillo A, Francia J. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause 2010;17:660-666.
48. Lewis JE, Nickell LA, Thompson LU, Szalai JP, Kiss A, Hilditch JR. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 2006;13:631-642. (Pubitemid 44079533)
49. Booth NL, Piersen CE, Banuvar S, Geller SE, Shulman LP, Farnsworth NR. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review. Menopause 2006;13:251-264.
50. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause [review]. Maturitas 2010;66:333-343.
51. Leclercq G, de Cremoux P, This P, Jacquot Y. Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes. Maturitas 2011;68:56-64.
52. de Cremoux P, This P, Leclercq G, Jacquot Y. Controversies concerning the use of phytoestrogens in menopause management: bioavailability and metabolism. Maturitas 2010;65:334-339.
53. Panay N. Integrating phytoestrogens with prescription medicinesVa conservative clinical approach to vasomotor symptom management. Maturitas 2007;57:90-94. (Pubitemid 46602897)
54. Elkind-Hirsch K. Effect of dietary phytoestrogens on hot flushes: can soy-based proteins substitute for traditional estrogen replacement therapy? Menopause 2001;8:154-156. (Pubitemid 32410986)
55. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007:CD001395.
56. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004;104:824-836. (Pubitemid 40458814)
57. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007;276:463-469. (Pubitemid 47415761)
58. Chedraui P, San Miguel G, Schwager G. The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass index. Gynecol Endocrinol 2011;27:307-313.
59. Rahman SA, Zainudin SR, Mun VL. Assessment of menopausal symptoms using modified Menopause Rating Scale (MRS) among middle age women in Kuching, Sarawak, Malaysia. Asia Pac Fam Med 2010;9:5.
60. Carmignani LO, Pedro AO, Costa-Paiva LH, Pinto-Neto AM. The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas 2010;67: 262-269.
61. Arakane M, Castillo C, Rosero MF, Penafiel R, Perez-Lopez FR, Chedraui P. Factors relating to insomnia during the menopausal transition as evaluated by the Insomnia Severity Index. Maturitas 2011;69:157-161.
62. Hachul H, Brandão LC, D'Almeida V, Bittencourt LRA, Baracat EC, Tufik S. Isoflavones decrease insomnia in postmenopause. Menopause 2011;18:178-184.
63. Hooper L, Ryder JJ, Kurzer MS, et al. Effects of soy protein and isoflavones on circulating hormone concentrations in pre-and postmenopausal women: a systematic review and meta-analysis. Hum Reprod Update 2009;15:423-440.
64. Meerts IA, Verspeek-Rip CM, Buskens CA, et al. Toxicological evaluation of pomegranate seed oil. Food Chem Toxicol 2009;47:1085-1092.